Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.03 +1.5%	$2.25	$0.40 ▼ $3.10	$329.83M	2.13	4.00 million shs	1.28 million shs
EDIT Editas Medicine	$2.73 +0.4%	$2.66	$0.91 ▼ $4.12	$244.58M	2.19	2.05 million shs	671,537 shs
GRFS Grifols	$9.84 +0.2%	$9.81	$6.19 ▼ $11.14	$6.75B	0.56	1.19 million shs	412,471 shs
SRPT Sarepta Therapeutics	$18.26 +1.1%	$17.86	$10.41 ▼ $140.97	$1.78B	0.46	15.10 million shs	8.00 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+1.50%	+1.50%	-15.42%	-15.42%	+70.59%
EDIT Editas Medicine	+0.37%	+3.80%	-13.33%	+45.99%	-30.36%
GRFS Grifols	+0.20%	-3.43%	-2.57%	+20.29%	+14.29%
SRPT Sarepta Therapeutics	+1.11%	-9.51%	+53.06%	-50.95%	-86.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTMX CytomX Therapeutics	4.3667 of 5 stars	3.5	1.0	0.0	4.7	3.8	1.7	1.3
EDIT Editas Medicine	4.4238 of 5 stars	3.1	4.0	0.0	4.3	3.3	2.5	0.6
GRFS Grifols	3.5827 of 5 stars	1.3	3.0	2.5	0.0	2.8	0.0	5.0
SRPT Sarepta Therapeutics	4.5548 of 5 stars	4.0	2.0	0.0	4.2	1.9	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	3.00	Buy	$5.75	183.25% Upside
EDIT Editas Medicine	2.23	Hold	$5.10	86.81% Upside
GRFS Grifols	2.60	Moderate Buy	$10.30	4.67% Upside
SRPT Sarepta Therapeutics	2.07	Hold	$43.50	138.23% Upside

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and GRFS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell ➝ Sell
8/20/2025	SRPT Sarepta Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$17.00
8/15/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $5.00
8/15/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$12.00
8/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $6.00
8/8/2025	GRFS Grifols	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/7/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$19.00
8/7/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$48.00 ➝ $50.00
8/5/2025	GRFS Grifols	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
7/31/2025	CTMX CytomX Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
7/29/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$22.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$138.10M	2.42	$0.37 per share	5.53	$0.73 per share	2.78
EDIT Editas Medicine	$32.31M	7.60	N/A	N/A	$0.21 per share	13.00
GRFS Grifols	$7.81B	0.87	$0.94 per share	10.49	$12.55 per share	0.78
SRPT Sarepta Therapeutics	$2.48B	0.72	$2.46 per share	7.41	$13.89 per share	1.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	$31.87M	$0.56	3.63	N/A	N/A	34.04%	158.70%	36.04%	11/6/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$2.85	N/A	N/A	N/A	-608.88%	-200.25%	-68.57%	11/3/2025 (Estimated)
GRFS Grifols	$169.80M	$1.17	8.41	9.37	0.34	N/A	N/A	N/A	11/5/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$0.87	N/A	1.67	N/A	-2.34%	-1.03%	-0.37%	11/5/2025 (Estimated)

Latest SRPT, CTMX, EDIT, and GRFS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	EDIT Editas Medicine	-$0.41	-$0.63	-$0.22	-$0.63	$1.81 million	$3.58 million
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	$2.02	+$1.13	$1.89	$530.66 million	$611.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
GRFS Grifols	$0.14	1.42%	N/A	11.97%	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest SRPT, CTMX, EDIT, and GRFS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2025	GRFS Grifols	--	$0.1404		8/12/2025	8/12/2025	8/20/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	4.20	4.20
EDIT Editas Medicine	N/A	2.77	2.77
GRFS Grifols	1.20	2.64	0.95
SRPT Sarepta Therapeutics	0.84	2.89	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
EDIT Editas Medicine	71.90%
GRFS Grifols	N/A
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	6.60%
EDIT Editas Medicine	1.90%
GRFS Grifols	0.19%
SRPT Sarepta Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	164.91 million	154.03 million	Optionable
EDIT Editas Medicine	230	89.92 million	88.21 million	Optionable
GRFS Grifols	23,822	687.55 million	686.25 million	Optionable
SRPT Sarepta Therapeutics	1,372	97.71 million	90.29 million	Optionable

SRPT, CTMX, EDIT, and GRFS Headlines

Recent News About These Companies

HC Wainwright Reaffirms "Sell" Rating for Sarepta Therapeutics (NASDAQ:SRPT)

1 hour ago | marketbeat.com

Sarepta Therapeutics' (SRPT) Sell Rating Reaffirmed at HC Wainwright

August 27 at 2:31 AM | americanbankingnews.com

Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

August 26 at 6:38 PM | finance.yahoo.com

University of Wisconsin Foundation Buys Shares of 27,717 Sarepta Therapeutics, Inc. $SRPT

August 26 at 7:23 AM | marketbeat.com

Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SRPT

August 26 at 5:06 AM | theglobeandmail.com

Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT

August 25 at 4:42 PM | globenewswire.com

Sarepta Therapeutics (SRPT): Assessing Valuation After Lawsuits and FDA Scrutiny Over ELEVIDYS Safety Concerns

August 25 at 1:56 PM | finance.yahoo.com

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

August 25 at 1:56 PM | tmcnet.com

Forecasting The Future: 44 Analyst Projections For Sarepta Therapeutics

August 25 at 1:56 PM | benzinga.com

SAREPTA FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline

August 25 at 12:04 PM | globenewswire.com

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

August 25 at 11:51 AM | mms.businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

August 25 at 10:38 AM | globenewswire.com

Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact The Gross Law Firm

August 25 at 8:45 AM | prnewswire.com

Sarepta Therapeutics (SRPT) Rating Update: HC Wainwright & Co. ...

August 25 at 8:30 AM | gurufocus.com

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. ...

August 25 at 4:30 AM | gurufocus.com

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. ...

August 25 at 4:30 AM | gurufocus.com

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

August 25 at 3:11 AM | prnewswire.com

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

August 25 at 3:10 AM | prnewswire.com

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 24 at 4:00 PM | globenewswire.com

Sarepta Therapeutics, Inc. $SRPT Shares Bought by T. Rowe Price Investment Management Inc.

August 24 at 6:16 AM | marketbeat.com

SRPT DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important ...

August 24 at 3:09 AM | barrons.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SRPT, CTMX, EDIT, and GRFS Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.03 +0.03 (+1.50%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$2.07 +0.04 (+1.77%)

As of 08:28 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Editas Medicine NASDAQ:EDIT

$2.73 +0.01 (+0.37%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$2.72 0.00 (-0.18%)

As of 08:30 AM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Grifols NASDAQ:GRFS

$9.84 +0.02 (+0.20%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$9.94 +0.11 (+1.07%)

As of 08:21 AM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Sarepta Therapeutics NASDAQ:SRPT

$18.26 +0.20 (+1.11%)

Closing price 08/26/2025 04:00 PM Eastern

Extended Trading

$18.28 +0.02 (+0.14%)

As of 08:30 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time